https://www.selleckchem.com/products/4sc-202.html
The primary outcome of the trial is change in exercise capacity, as measured by the 6-minute walk test distance at 12 months compared to baseline. Secondary endpoints include improvements in cardiovascular risk factor status and quality of life, received dose intensity of chemotherapy and major adverse cardiovascular events. Multicentre ethical approval has been granted by the Austin Hospital (HREC/47081/Austin/2018). The analysed results will be published in a peer reviewed journal on completion of the clinical trial. SMART-BREAST has
Like
Comment
Share
